文献速递造血干细胞移植与细胞治疗

胃肠道抗原呈递细胞在致死性移植物抗宿主病中的首要作用

The primacy of gastrointestinal tract antigen-presenting cells in lethal graft-versus-host disease.
PubMed 文献 · Blood · 2019-01-01

异基因造血干细胞移植是高危血液肿瘤的根治手段,但受GVHD限制。GVHD由受者抗原呈递细胞与供者T细胞相互作用启动,驱动T细胞向致病性1型和17型分化。本文综述了胃肠道专业与非专业APC在移植围期受PAMP/DAMP信号修饰,供者DC在结肠扩张并迁移至肠系膜淋巴结致敏新供者T细胞,形成致死性正反馈级联。

要点

  • 胃肠道APC是启动GVHD的关键细胞群
  • PAMP/DAMP信号修饰APC并驱动供者DC扩增
  • 靶向抑制胃肠道APC功能是潜在治疗策略

核心结论

  • 胃肠道专业和非专业抗原呈递细胞在启动致死性GVHD中起首要作用。

研究设计与样本

  • 本文为综述,未报告系统检索范围与样本量。

主要发现

  • GVHD由受者APC与供者T细胞相互作用启动,驱动T细胞向致病性1型和17型分化而牺牲耐受性调节性T细胞。
  • 1型和17型T细胞分泌GM-CSF和IFN-γ等细胞因子,放大细胞因子风暴并促进供者APC扩增和同种抗原呈递。
  • 移植围期胃肠道APC受预处理和肠道微生物群衍生的PAMP/DAMP信号深刻修饰。
  • 黏膜屏障受损后,结肠DAMP/PAMP信号进入固有层激活供者DC,导致供者DC扩增、同种抗原呈递并迁移至肠系膜淋巴结。
  • 在肠系膜淋巴结中新供者T细胞被致敏、扩增、分化并印迹肠道归巢整合素,迁移至受损胃肠道形成致死性正反馈级联。

临床怎么用

  • 治疗策略可聚焦于抑制胃肠道APC功能以阻断GVHD启动。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic stem cell transplantation is a cornerstone of curative therapy for high-risk and/or advanced hematological malignancies but remains limited by graft-versus-host disease (GVHD). GVHD is initiated by the interaction between recipient antigen-presenting cells (APCs) and donor T cells, culminating in T-cell differentiation along pathogenic type-1 and type-17 paradigms at the expense of tolerogenic regulatory T-cell patterns. Type-1 and type-17 T cells secrete cytokines (eg, granulocyte-macrophage colony-stimulating factor and interferon-γ) critical to the cytokine storm that amplifies expansion of donor APCs and their alloantigen presentation. It has become increasingly clear that pathogenic donor T-cell differentiation is initiated by both professional recipient APCs (eg, dendritic cells [DCs]) and nonprofessional APCs (eg, epithelial and mesenchymal cells), particularly within the gastrointestinal (GI) tract. In the immediate peritransplantation period, these APCs are profoundly modified by pathogen-associated molecular pattern (PAMP)/damage-associated molecular pattern (DAMP) signals derived from conditioning and intestinal microbiota. Subsequently, donor DCs in the GI tract are activated by DAMP/PAMP signals in the colon that gain access to the lamina propria once the mucosal barrier mucosa is compromised by GVHD. This results in donor DC expansion and alloantigen presentation in the colon and subsequent migration into the mesenteric lymph nodes. Here, new donor T cells are primed, expanded, differentiated, and imprinted with gut-homing integrins permissive of migration into the damaged GI tract, resulting in the lethal feed-forward cascade of GVHD. These new insights into our understanding of the cellular and molecular factors initiating GVHD, both spatially and temporally, give rise to a number of logical therapeutic targets, focusing on the inhibition of APC function in the GI tract.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Koyama M, Hill GR. The primacy of gastrointestinal tract antigen-presenting cells in lethal graft-versus-host disease. Blood. 2019. PMID: 31697827. doi:10.1182/blood.2019000823

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。